Genya Frid, MD
Internal Medicine · New Hyde Park, NYNPI 1801858055
Payments from drug & device makers
Across 315 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$991
- AbbVie$951
- Amgen$783
- Boehringer Ingelheim$524
- GSK$451
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,703100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $1,192 |
| AstraZeneca | 46 | $991 |
| AbbVie(2 entities) | 45 | $951 |
| Amgen(2 entities) | 24 | $783 |
| Boehringer Ingelheim | 17 | $524 |
| GSK | 23 | $451 |
| E.r. Squibb & Sons, L.L.C. | 13 | $293 |
| Novartis | 12 | $280 |
| Lilly USA, LLC | 13 | $254 |
| Ipsen Biopharmaceuticals, Inc | 2 | $250 |
| Pfizer | 13 | $248 |
| Alnylam Pharmaceuticals Inc. | 2 | $245 |
| Abbott | 5 | $199 |
| Johnson & Johnson(2 entities) | 9 | $146 |
| Amneal Pharmaceuticals LLC | 6 | $128 |
| Boston Scientific | 2 | $128 |
| Merck | 7 | $119 |
| Phathom Pharmaceuticals, Inc. | 1 | $108 |
| Kowa Pharmaceuticals America, Inc. | 5 | $79 |
| Exact Sciences | 3 | $55 |
| Eisai Inc. | 2 | $40 |
| Mylan Specialty L.p. | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Althera Pharmaceuticals LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
| Ardelyx, Inc. | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,703 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 49 | $55,928 |
| TrulicityDulaglutide | 34 | $55,005 |
| OzempicSemaglutide | 28 | $50,504 |
| JardianceEmpagliflozin | 34 | $48,160 |
| FarxigaDapagliflozin Propanediol | 28 | $40,835 |
| JanuviaSitagliptin Phosphate | 24 | $29,104 |
| SynthroidLevothyroxine Sodium | 73 | $4,075 |
| Rosuvastatin Calcium | 266 | $3,945 |
| Irbesartan | 96 | $2,389 |
| Levothyroxine Sodium | 216 | $2,298 |
| Atorvastatin Calcium | 257 | $1,864 |
| Metoprolol Succinate | 157 | $1,764 |
| Pitavastatin Calcium | 12 | $1,502 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,466 |
| Valsartan | 64 | $1,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $248 | $55,92849 claims |
| Lilly USA, LLCTrulicity | $254 | $55,00534 claims |
| Novo NordiskOzempic | $1,192 | $50,50428 claims |
| Boehringer IngelheimJardiance | $524 | $48,16034 claims |
| AstraZenecaFarxiga | $991 | $40,83528 claims |
| MerckJanuvia | $119 | $29,10424 claims |
| AbbVieSynthroid | $951 | $4,07573 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $128 | $2,298216 claims |
| Almatica Pharma LLCSertraline Hcl | $18 | $82190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New Hyde Park
- Nagashree SeetharamuNew Hyde Park$2.5M
- Janice WangNew Hyde Park$2.1M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.